26RFa, a novel orexigenic neuropeptide, inhibits insulin secretion in the rat pancreas

Peptides. 2007 Apr;28(4):725-30. doi: 10.1016/j.peptides.2006.04.004. Epub 2006 Jun 13.

Abstract

26RFa is a novel orexigenic neuropeptide identified as the endogenous ligand of the orphan G protein-coupled receptor GPR103. GPR103 shares sequence identity with the receptors for neuropeptide-Y and galanin, two peptides known to inhibit insulin secretion. We have investigated the effect of 26RFa on insulin and glucagon secretion in the perfused rat pancreas. 26RFa dose-dependently reduced glucose-induced insulin release, inhibited the insulin responses to both arginine and exendin-4 and did not affect glucagon output. The inhibitory effect of 26RFa on exendin-4-induced insulin secretion was not observed in pancreata from pertussis toxin-treated rats, thus suggesting that 26RFa may inhibit insulin secretion, at least in part, via a pertussis toxin-sensitive G(i) protein coupled to the adenylyl cyclase system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Dose-Response Relationship, Drug
  • Glucagon / metabolism
  • Glucose / pharmacology
  • Humans
  • In Vitro Techniques
  • Insulin / metabolism*
  • Insulin Secretion
  • Male
  • Mice
  • Molecular Sequence Data
  • Neuropeptides / chemical synthesis
  • Neuropeptides / chemistry
  • Neuropeptides / pharmacology*
  • Pancreas / drug effects*
  • Pancreas / metabolism
  • Rats
  • Rats, Wistar

Substances

  • Insulin
  • Neuropeptides
  • Glucagon
  • Glucose